Navicular syndrome is a condition affecting the navicular bone structures.
It often occurs in both front feet of the horse and is most typically seen in mature riding horses, with Thoroughbreds and Quarter Horses being more susceptible. If left untreated it can lead to significant and even disabling lameness, with common manifestations including a shortening of the stride and increased tendency to stumble due to altered foot placement.
Navicular syndrome can lead to an imbalance in the bone remodelling process, resulting in excessive navicular bone resorption and/or abnormal mineralizations. This leads to more of the bone being dissolved than is replaced, leading to mineral loss and a weakening of the bone structure over time.
The horse has a sesamoid bone called the navicular bone, located within the hoof.
The navicular region is an important structure in relation to lameness, particularly in the front feet, and is involved with a significant disease process called navicular disease or navicular syndrome.
Newer imaging techniques have shown that damage to the soft tissues in the region may be significant contributors to lameness and that multiple causes may result in visible lameness.
OSPHOS® (clodronate injection) is a safe and effective FDA-approved treatment from Dechra Veterinary Products for the control of clinical signs associated with navicular syndrome in horses 4 years of age and older. The use of OSPHOS in horses less than 4 years of age has not been studied.
Dechra Veterinary Products proudly distributed by The Veterinary Group.
To find out more visit our website at:
thevet.group/
Or our socials:
/ theveterinarygroup
/ thevet.group